Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility

Illawarra and Shoalhaven Local Health District0 个研究点目标入组 10 人开始时间: 2015年5月20日最近更新: 2022年3月7日

适应症

试验速览

暂无简介。

•1. Histologically proven unresectable biliary tract cancer
•2. Prior chemotherapy with gemcitabine/platinum. Patient must have either progressed on chemotherapy or be intolerant to either drug.
•3. >18 years
•4. Measurable disease according to RECIST
•5. Good performance status
•6. Adequate bone marrow function
•7. Adequate hepatic function
•8. Adequate renal function
•9 Planned to start treatment within 30 days of registration
•10. Willing and able to comply with study requirements
•11. Signed, written informed consent

•1. Previous treatment with a taxane or fluoropyrimidines
•2. Prior hypersensitivity to paclitaxel or albumin
•3. Significant underlying medical conditions that may be aggravated by study treatment
•4. Significant peripheral neuropathy
•5. Life expectancy of less than 3 months
•6. Untreated brain metastases or leptomeningeal disease
•7. History of another malignancy within 2 years prior to registration.
•8. Concurrent illness including severe infection
•9. Presence of any psychological, familial, sociological or geographical condition that may hamper compliance
•10. Pregnancy, lactation, or inadequate contraception

发起方

Illawarra and Shoalhaven Local Health District